View Financial HealthBeacon Pharmaceuticals 배당 및 자사주 매입배당 기준 점검 3/6Beacon Pharmaceuticals 수익으로 충분히 충당되는 현재 수익률 2.01% 보유한 배당금 지급 회사입니다.핵심 정보2.0%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률17.8%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향39%최근 배당 및 자사주 매입 업데이트공시 • Oct 24Beacon Pharmaceuticals PLC announces Annual dividend, payable on January 22, 2026Beacon Pharmaceuticals PLC announced Annual dividend of BDT 2.1000 per share payable on January 22, 2026, ex-date on November 17, 2025 and record date on November 16, 2025.Upcoming Dividend • Oct 21Upcoming dividend of ৳2.00 per shareEligible shareholders must have bought the stock before 28 October 2024. Payment date: 22 January 2025. Payout ratio is a comfortable 56% but the company is not cash flow positive. Trailing yield: 1.8%. Lower than top quartile of Bangladeshi dividend payers (4.8%). Lower than average of industry peers (3.6%).Upcoming Dividend • Nov 12Upcoming dividend of ৳1.60 per share at 0.7% yieldEligible shareholders must have bought the stock before 19 November 2023. Payment date: 23 January 2024. Payout ratio is a comfortable 39% but the company is paying out more than the cash it is generating. Trailing yield: 0.7%. Lower than top quartile of Bangladeshi dividend payers (3.3%). Lower than average of industry peers (2.5%).공시 • Oct 26Beacon Pharmaceuticals plc Recommends Cash Dividend for the Year Ended June 30, 2023Beacon Pharmaceuticals PLC has recommended 16% Cash Dividend for the year ended June 30, 2023.공시 • Oct 27Beacon Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2022The Board of Directors of Beacon Pharmaceuticals Ltd. has recommended 16% cash dividend for the year ended on June 30, 2022.Upcoming Dividend • Dec 14Upcoming dividend of ৳1.50 per shareEligible shareholders must have bought the stock before 21 December 2021. Payment date: 30 January 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Lower than average of industry peers (1.8%).모든 업데이트 보기Recent updates공시 • Apr 21Beacon Pharmaceuticals PLC to Report Q3, 2026 Results on Apr 27, 2026Beacon Pharmaceuticals PLC announced that they will report Q3, 2026 results on Apr 27, 2026공시 • Jan 22Beacon Pharmaceuticals PLC to Report Q2, 2026 Results on Jan 28, 2026Beacon Pharmaceuticals PLC announced that they will report Q2, 2026 results on Jan 28, 2026공시 • Nov 07Beacon Pharmaceuticals PLC to Report Q1, 2026 Results on Nov 11, 2025Beacon Pharmaceuticals PLC announced that they will report Q1, 2026 results on Nov 11, 2025공시 • Oct 24Beacon Pharmaceuticals PLC announces Annual dividend, payable on January 22, 2026Beacon Pharmaceuticals PLC announced Annual dividend of BDT 2.1000 per share payable on January 22, 2026, ex-date on November 17, 2025 and record date on November 16, 2025.공시 • Oct 23Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2025Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2025, at 11:00 Central Asia Standard Time. Location: hybrid platform., Bangladesh공시 • Oct 21Beacon Pharmaceuticals PLC to Report Fiscal Year 2025 Results on Oct 22, 2025Beacon Pharmaceuticals PLC announced that they will report fiscal year 2025 results on Oct 22, 2025공시 • Apr 23Beacon Pharmaceuticals PLC to Report Q3, 2025 Results on Apr 29, 2025Beacon Pharmaceuticals PLC announced that they will report Q3, 2025 results on Apr 29, 2025공시 • Jan 20Beacon Pharmaceuticals PLC to Report Q2, 2025 Results on Jan 29, 2025Beacon Pharmaceuticals PLC announced that they will report Q2, 2025 results on Jan 29, 2025공시 • Oct 25Beacon Pharmaceuticals PLC to Report Q1, 2025 Results on Oct 29, 2024Beacon Pharmaceuticals PLC announced that they will report Q1, 2025 results on Oct 29, 2024Upcoming Dividend • Oct 21Upcoming dividend of ৳2.00 per shareEligible shareholders must have bought the stock before 28 October 2024. Payment date: 22 January 2025. Payout ratio is a comfortable 56% but the company is not cash flow positive. Trailing yield: 1.8%. Lower than top quartile of Bangladeshi dividend payers (4.8%). Lower than average of industry peers (3.6%).Valuation Update With 7 Day Price Move • Oct 07Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ৳113, the stock trades at a trailing P/E ratio of 56x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 50% over the past three years.공시 • Oct 01Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2024Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2024, at 11:00 Central Asia Standard Time.공시 • Sep 19Beacon Pharmaceuticals PLC to Report Fiscal Year 2024 Results on Sep 29, 2024Beacon Pharmaceuticals PLC announced that they will report fiscal year 2024 results on Sep 29, 2024Valuation Update With 7 Day Price Move • Sep 10Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ৳137, the stock trades at a trailing P/E ratio of 68.1x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 37% over the past three years.Reported Earnings • May 18Third quarter 2024 earnings released: ৳0.95 loss per share (vs ৳0.037 loss in 3Q 2023)Third quarter 2024 results: ৳0.95 loss per share (further deteriorated from ৳0.037 loss in 3Q 2023). Revenue: ৳2.64b (up 23% from 3Q 2023). Net loss: ৳220.3m (loss widened ৳211.6m from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.공시 • May 08Beacon Pharmaceuticals PLC to Report Q3, 2024 Results on May 12, 2024Beacon Pharmaceuticals PLC announced that they will report Q3, 2024 results on May 12, 2024New Risk • Apr 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.6x net interest cover). Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Profit margins are more than 30% lower than last year (7.0% net profit margin).New Risk • Feb 14New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 27% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.6x net interest cover). High level of non-cash earnings (27% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (7.0% net profit margin).공시 • Jan 30Beacon Pharmaceuticals plc Announces Appointment of Md. Sahabuddin FCS as Company SecretaryBeacon Pharmaceuticals PLC has informed that the Board of Directors has appointed Mr. Md. Sahabuddin FCS as the Company Secretary of the Company with immediate effect.공시 • Jan 26Beacon Pharmaceuticals PLC to Report Q2, 2024 Results on Jan 28, 2024Beacon Pharmaceuticals PLC announced that they will report Q2, 2024 results on Jan 28, 2024Reported Earnings • Jan 25First quarter 2024 earnings released: EPS: ৳1.60 (vs ৳0.99 in 1Q 2023)First quarter 2024 results: EPS: ৳1.60 (up from ৳0.99 in 1Q 2023). Revenue: ৳2.32b (up 15% from 1Q 2023). Net income: ৳369.5m (up 62% from 1Q 2023). Profit margin: 16% (up from 11% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings.Reported Earnings • Dec 07Full year 2023 earnings released: EPS: ৳2.21 (vs ৳4.05 in FY 2022)Full year 2023 results: EPS: ৳2.21 (down from ৳4.05 in FY 2022). Revenue: ৳8.51b (up 6.1% from FY 2022). Net income: ৳509.8m (down 46% from FY 2022). Profit margin: 6.0% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Nov 20New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (101% net debt to equity). Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Profit margins are more than 30% lower than last year (8.6% net profit margin).Upcoming Dividend • Nov 12Upcoming dividend of ৳1.60 per share at 0.7% yieldEligible shareholders must have bought the stock before 19 November 2023. Payment date: 23 January 2024. Payout ratio is a comfortable 39% but the company is paying out more than the cash it is generating. Trailing yield: 0.7%. Lower than top quartile of Bangladeshi dividend payers (3.3%). Lower than average of industry peers (2.5%).공시 • Nov 08Beacon Pharmaceuticals PLC to Report Q1, 2024 Results on Nov 13, 2023Beacon Pharmaceuticals PLC announced that they will report Q1, 2024 results on Nov 13, 2023공시 • Oct 26Beacon Pharmaceuticals plc Recommends Cash Dividend for the Year Ended June 30, 2023Beacon Pharmaceuticals PLC has recommended 16% Cash Dividend for the year ended June 30, 2023.공시 • Oct 24Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 24, 2023Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 24, 2023, at 11:00 Bangladesh Standard Time.공시 • Oct 17Beacon Pharmaceuticals PLC to Report Q3, 2023 Results on Oct 22, 2023Beacon Pharmaceuticals PLC announced that they will report Q3, 2023 results on Oct 22, 2023공시 • Jun 20Beacon Pharmaceuticals PLC Announces Appointment of Jalal Uddin as Chief Financial OfficerBeacon Pharmaceuticals PLC announced that the Board of Directors has appointed Mr. Md. Jalal Uddin, FCA as Chief Financial Officer of the company with effect from June 06, 2023.공시 • May 12+ 1 more updateBeacon Pharmaceuticals plc Announces Resignation of Abdul Haque Sarder as CFOBeacon Pharmaceuticals PLC informed that Mr. Md. Abdul Haque Sarder, FCS, FCA, CFO of the company resigned from his position with effect from May 09, 2023.Reported Earnings • May 07Third quarter 2023 earnings released: ৳0.037 loss per share (vs ৳0.99 profit in 3Q 2022)Third quarter 2023 results: ৳0.037 loss per share (down from ৳0.99 profit in 3Q 2022). Revenue: ৳2.15b (up 16% from 3Q 2022). Net loss: ৳8.66m (down 104% from profit in 3Q 2022).Reported Earnings • Feb 17Second quarter 2023 earnings released: EPS: ৳1.61 (vs ৳1.07 in 2Q 2022)Second quarter 2023 results: EPS: ৳1.61 (up from ৳1.07 in 2Q 2022). Revenue: ৳2.19b (up 5.5% from 2Q 2022). Net income: ৳370.9m (up 51% from 2Q 2022). Profit margin: 17% (up from 12% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 82% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Dec 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Mohammad Sanaullah was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 24First quarter 2023 earnings released: EPS: ৳0.99 (vs ৳1.52 in 1Q 2022)First quarter 2023 results: EPS: ৳0.99 (down from ৳1.52 in 1Q 2022). Revenue: ৳2.02b (down 11% from 1Q 2022). Net income: ৳228.8m (down 35% from 1Q 2022). Profit margin: 11% (down from 16% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Director Mohammad Karim was the last director to join the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Oct 27Beacon Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2022The Board of Directors of Beacon Pharmaceuticals Ltd. has recommended 16% cash dividend for the year ended on June 30, 2022.Valuation Update With 7 Day Price Move • Sep 25Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ৳315, the stock trades at a trailing P/E ratio of 77.7x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 1,087% over the past three years.Valuation Update With 7 Day Price Move • Sep 07Investor sentiment improved over the past weekAfter last week's 24% share price gain to ৳320, the stock trades at a trailing P/E ratio of 79x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 1,040% over the past three years.Reported Earnings • May 22Third quarter 2022 earnings released: EPS: ৳0.99 (vs ৳2.01 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.99 (down from ৳2.01 in 3Q 2021). Revenue: ৳1.84b (down 29% from 3Q 2021). Net income: ৳228.9m (down 51% from 3Q 2021). Profit margin: 12% (down from 18% in 3Q 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has increased by 147% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Director Mohammad Karim was the last director to join the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Feb 12Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: EPS: ৳1.07 (up from ৳1.02 in 2Q 2021). Revenue: ৳2.08b (down 4.8% from 2Q 2021). Net income: ৳246.3m (up 5.1% from 2Q 2021). Profit margin: 12% (up from 11% in 2Q 2021). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has increased by 126% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Dec 14Upcoming dividend of ৳1.50 per shareEligible shareholders must have bought the stock before 21 December 2021. Payment date: 30 January 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Lower than average of industry peers (1.8%).Reported Earnings • Jun 24Third quarter 2020 earnings released: EPS ৳0.25 (vs ৳0.20 in 3Q 2019)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ৳1.37b (up 18% from 3Q 2019). Net income: ৳58.7m (up 24% from 3Q 2019). Profit margin: 4.3% (up from 4.1% in 3Q 2019). The increase in margin was driven by higher revenue.Is New 90 Day High Low • Feb 25New 90-day high: ৳103The company is up 50% from its price of ৳68.20 on 26 November 2020. The Bangladeshi market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 12% over the same period.Is New 90 Day High Low • Feb 01New 90-day high: ৳84.30The company is up 5.0% from its price of ৳80.00 on 03 November 2020. The Bangladeshi market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 21% over the same period.Is New 90 Day High Low • Nov 30New 90-day low: ৳66.50The company is down 17% from its price of ৳79.80 on 01 September 2020. The Bangladeshi market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.Reported Earnings • Nov 26Third quarter 2020 earnings released: EPS ৳0.25The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ৳1.37b (up 18% from 3Q 2019). Net income: ৳58.7m (up 24% from 3Q 2019). Profit margin: 4.3% (up from 4.1% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth.공시 • Jul 07Beacon Pharmaceuticals Ltd. to Report Q3, 2020 Results on Jun 25, 2020Beacon Pharmaceuticals Ltd. announced that they will report Q3, 2020 results on Jun 25, 2020지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 배당금 지급이 안정적인 반면, BEACONPHAR 은(는) 배당금을 지급한 지 10년도 채 되지 않았습니다.배당금 증가: BEACONPHAR 의 배당금 지급이 증가했지만 회사는 9 년 동안만 배당금을 지급했습니다.배당 수익률 vs 시장Beacon Pharmaceuticals 배당 수익률 vs 시장BEACONPHAR의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (BEACONPHAR)2.0%시장 하위 25% (BD)0.7%시장 상위 25% (BD)3.6%업계 평균 (Pharmaceuticals)3.8%분석가 예측 (BEACONPHAR) (최대 3년)n/a주목할만한 배당금: BEACONPHAR 의 배당금( 2.01% )은 BD 시장에서 배당금 지급자의 하위 25%( 0.74% )보다 높습니다.고배당: BEACONPHAR 의 배당금( 2.01% )은 BD 시장에서 배당금 지급자의 상위 25%( 3.61% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 합리적으로 낮은 지불 비율 ( 39.2% )로 BEACONPHAR 의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: 합리적인 현금 지급 비율 ( 66.9% )로 BEACONPHAR 의 배당금 지급은 현금 흐름으로 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YBD 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/11 23:02종가2026/06/11 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Beacon Pharmaceuticals PLC는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Oct 24Beacon Pharmaceuticals PLC announces Annual dividend, payable on January 22, 2026Beacon Pharmaceuticals PLC announced Annual dividend of BDT 2.1000 per share payable on January 22, 2026, ex-date on November 17, 2025 and record date on November 16, 2025.
Upcoming Dividend • Oct 21Upcoming dividend of ৳2.00 per shareEligible shareholders must have bought the stock before 28 October 2024. Payment date: 22 January 2025. Payout ratio is a comfortable 56% but the company is not cash flow positive. Trailing yield: 1.8%. Lower than top quartile of Bangladeshi dividend payers (4.8%). Lower than average of industry peers (3.6%).
Upcoming Dividend • Nov 12Upcoming dividend of ৳1.60 per share at 0.7% yieldEligible shareholders must have bought the stock before 19 November 2023. Payment date: 23 January 2024. Payout ratio is a comfortable 39% but the company is paying out more than the cash it is generating. Trailing yield: 0.7%. Lower than top quartile of Bangladeshi dividend payers (3.3%). Lower than average of industry peers (2.5%).
공시 • Oct 26Beacon Pharmaceuticals plc Recommends Cash Dividend for the Year Ended June 30, 2023Beacon Pharmaceuticals PLC has recommended 16% Cash Dividend for the year ended June 30, 2023.
공시 • Oct 27Beacon Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2022The Board of Directors of Beacon Pharmaceuticals Ltd. has recommended 16% cash dividend for the year ended on June 30, 2022.
Upcoming Dividend • Dec 14Upcoming dividend of ৳1.50 per shareEligible shareholders must have bought the stock before 21 December 2021. Payment date: 30 January 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Lower than average of industry peers (1.8%).
공시 • Apr 21Beacon Pharmaceuticals PLC to Report Q3, 2026 Results on Apr 27, 2026Beacon Pharmaceuticals PLC announced that they will report Q3, 2026 results on Apr 27, 2026
공시 • Jan 22Beacon Pharmaceuticals PLC to Report Q2, 2026 Results on Jan 28, 2026Beacon Pharmaceuticals PLC announced that they will report Q2, 2026 results on Jan 28, 2026
공시 • Nov 07Beacon Pharmaceuticals PLC to Report Q1, 2026 Results on Nov 11, 2025Beacon Pharmaceuticals PLC announced that they will report Q1, 2026 results on Nov 11, 2025
공시 • Oct 24Beacon Pharmaceuticals PLC announces Annual dividend, payable on January 22, 2026Beacon Pharmaceuticals PLC announced Annual dividend of BDT 2.1000 per share payable on January 22, 2026, ex-date on November 17, 2025 and record date on November 16, 2025.
공시 • Oct 23Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2025Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2025, at 11:00 Central Asia Standard Time. Location: hybrid platform., Bangladesh
공시 • Oct 21Beacon Pharmaceuticals PLC to Report Fiscal Year 2025 Results on Oct 22, 2025Beacon Pharmaceuticals PLC announced that they will report fiscal year 2025 results on Oct 22, 2025
공시 • Apr 23Beacon Pharmaceuticals PLC to Report Q3, 2025 Results on Apr 29, 2025Beacon Pharmaceuticals PLC announced that they will report Q3, 2025 results on Apr 29, 2025
공시 • Jan 20Beacon Pharmaceuticals PLC to Report Q2, 2025 Results on Jan 29, 2025Beacon Pharmaceuticals PLC announced that they will report Q2, 2025 results on Jan 29, 2025
공시 • Oct 25Beacon Pharmaceuticals PLC to Report Q1, 2025 Results on Oct 29, 2024Beacon Pharmaceuticals PLC announced that they will report Q1, 2025 results on Oct 29, 2024
Upcoming Dividend • Oct 21Upcoming dividend of ৳2.00 per shareEligible shareholders must have bought the stock before 28 October 2024. Payment date: 22 January 2025. Payout ratio is a comfortable 56% but the company is not cash flow positive. Trailing yield: 1.8%. Lower than top quartile of Bangladeshi dividend payers (4.8%). Lower than average of industry peers (3.6%).
Valuation Update With 7 Day Price Move • Oct 07Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ৳113, the stock trades at a trailing P/E ratio of 56x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 50% over the past three years.
공시 • Oct 01Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2024Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2024, at 11:00 Central Asia Standard Time.
공시 • Sep 19Beacon Pharmaceuticals PLC to Report Fiscal Year 2024 Results on Sep 29, 2024Beacon Pharmaceuticals PLC announced that they will report fiscal year 2024 results on Sep 29, 2024
Valuation Update With 7 Day Price Move • Sep 10Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ৳137, the stock trades at a trailing P/E ratio of 68.1x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 37% over the past three years.
Reported Earnings • May 18Third quarter 2024 earnings released: ৳0.95 loss per share (vs ৳0.037 loss in 3Q 2023)Third quarter 2024 results: ৳0.95 loss per share (further deteriorated from ৳0.037 loss in 3Q 2023). Revenue: ৳2.64b (up 23% from 3Q 2023). Net loss: ৳220.3m (loss widened ৳211.6m from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
공시 • May 08Beacon Pharmaceuticals PLC to Report Q3, 2024 Results on May 12, 2024Beacon Pharmaceuticals PLC announced that they will report Q3, 2024 results on May 12, 2024
New Risk • Apr 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.6x net interest cover). Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Profit margins are more than 30% lower than last year (7.0% net profit margin).
New Risk • Feb 14New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 27% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.6x net interest cover). High level of non-cash earnings (27% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (7.0% net profit margin).
공시 • Jan 30Beacon Pharmaceuticals plc Announces Appointment of Md. Sahabuddin FCS as Company SecretaryBeacon Pharmaceuticals PLC has informed that the Board of Directors has appointed Mr. Md. Sahabuddin FCS as the Company Secretary of the Company with immediate effect.
공시 • Jan 26Beacon Pharmaceuticals PLC to Report Q2, 2024 Results on Jan 28, 2024Beacon Pharmaceuticals PLC announced that they will report Q2, 2024 results on Jan 28, 2024
Reported Earnings • Jan 25First quarter 2024 earnings released: EPS: ৳1.60 (vs ৳0.99 in 1Q 2023)First quarter 2024 results: EPS: ৳1.60 (up from ৳0.99 in 1Q 2023). Revenue: ৳2.32b (up 15% from 1Q 2023). Net income: ৳369.5m (up 62% from 1Q 2023). Profit margin: 16% (up from 11% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings.
Reported Earnings • Dec 07Full year 2023 earnings released: EPS: ৳2.21 (vs ৳4.05 in FY 2022)Full year 2023 results: EPS: ৳2.21 (down from ৳4.05 in FY 2022). Revenue: ৳8.51b (up 6.1% from FY 2022). Net income: ৳509.8m (down 46% from FY 2022). Profit margin: 6.0% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Nov 20New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (101% net debt to equity). Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Profit margins are more than 30% lower than last year (8.6% net profit margin).
Upcoming Dividend • Nov 12Upcoming dividend of ৳1.60 per share at 0.7% yieldEligible shareholders must have bought the stock before 19 November 2023. Payment date: 23 January 2024. Payout ratio is a comfortable 39% but the company is paying out more than the cash it is generating. Trailing yield: 0.7%. Lower than top quartile of Bangladeshi dividend payers (3.3%). Lower than average of industry peers (2.5%).
공시 • Nov 08Beacon Pharmaceuticals PLC to Report Q1, 2024 Results on Nov 13, 2023Beacon Pharmaceuticals PLC announced that they will report Q1, 2024 results on Nov 13, 2023
공시 • Oct 26Beacon Pharmaceuticals plc Recommends Cash Dividend for the Year Ended June 30, 2023Beacon Pharmaceuticals PLC has recommended 16% Cash Dividend for the year ended June 30, 2023.
공시 • Oct 24Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 24, 2023Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 24, 2023, at 11:00 Bangladesh Standard Time.
공시 • Oct 17Beacon Pharmaceuticals PLC to Report Q3, 2023 Results on Oct 22, 2023Beacon Pharmaceuticals PLC announced that they will report Q3, 2023 results on Oct 22, 2023
공시 • Jun 20Beacon Pharmaceuticals PLC Announces Appointment of Jalal Uddin as Chief Financial OfficerBeacon Pharmaceuticals PLC announced that the Board of Directors has appointed Mr. Md. Jalal Uddin, FCA as Chief Financial Officer of the company with effect from June 06, 2023.
공시 • May 12+ 1 more updateBeacon Pharmaceuticals plc Announces Resignation of Abdul Haque Sarder as CFOBeacon Pharmaceuticals PLC informed that Mr. Md. Abdul Haque Sarder, FCS, FCA, CFO of the company resigned from his position with effect from May 09, 2023.
Reported Earnings • May 07Third quarter 2023 earnings released: ৳0.037 loss per share (vs ৳0.99 profit in 3Q 2022)Third quarter 2023 results: ৳0.037 loss per share (down from ৳0.99 profit in 3Q 2022). Revenue: ৳2.15b (up 16% from 3Q 2022). Net loss: ৳8.66m (down 104% from profit in 3Q 2022).
Reported Earnings • Feb 17Second quarter 2023 earnings released: EPS: ৳1.61 (vs ৳1.07 in 2Q 2022)Second quarter 2023 results: EPS: ৳1.61 (up from ৳1.07 in 2Q 2022). Revenue: ৳2.19b (up 5.5% from 2Q 2022). Net income: ৳370.9m (up 51% from 2Q 2022). Profit margin: 17% (up from 12% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 82% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Dec 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Mohammad Sanaullah was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 24First quarter 2023 earnings released: EPS: ৳0.99 (vs ৳1.52 in 1Q 2022)First quarter 2023 results: EPS: ৳0.99 (down from ৳1.52 in 1Q 2022). Revenue: ৳2.02b (down 11% from 1Q 2022). Net income: ৳228.8m (down 35% from 1Q 2022). Profit margin: 11% (down from 16% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Director Mohammad Karim was the last director to join the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Oct 27Beacon Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2022The Board of Directors of Beacon Pharmaceuticals Ltd. has recommended 16% cash dividend for the year ended on June 30, 2022.
Valuation Update With 7 Day Price Move • Sep 25Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ৳315, the stock trades at a trailing P/E ratio of 77.7x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 1,087% over the past three years.
Valuation Update With 7 Day Price Move • Sep 07Investor sentiment improved over the past weekAfter last week's 24% share price gain to ৳320, the stock trades at a trailing P/E ratio of 79x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 1,040% over the past three years.
Reported Earnings • May 22Third quarter 2022 earnings released: EPS: ৳0.99 (vs ৳2.01 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.99 (down from ৳2.01 in 3Q 2021). Revenue: ৳1.84b (down 29% from 3Q 2021). Net income: ৳228.9m (down 51% from 3Q 2021). Profit margin: 12% (down from 18% in 3Q 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has increased by 147% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Director Mohammad Karim was the last director to join the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Feb 12Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: EPS: ৳1.07 (up from ৳1.02 in 2Q 2021). Revenue: ৳2.08b (down 4.8% from 2Q 2021). Net income: ৳246.3m (up 5.1% from 2Q 2021). Profit margin: 12% (up from 11% in 2Q 2021). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has increased by 126% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Dec 14Upcoming dividend of ৳1.50 per shareEligible shareholders must have bought the stock before 21 December 2021. Payment date: 30 January 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Lower than average of industry peers (1.8%).
Reported Earnings • Jun 24Third quarter 2020 earnings released: EPS ৳0.25 (vs ৳0.20 in 3Q 2019)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ৳1.37b (up 18% from 3Q 2019). Net income: ৳58.7m (up 24% from 3Q 2019). Profit margin: 4.3% (up from 4.1% in 3Q 2019). The increase in margin was driven by higher revenue.
Is New 90 Day High Low • Feb 25New 90-day high: ৳103The company is up 50% from its price of ৳68.20 on 26 November 2020. The Bangladeshi market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 12% over the same period.
Is New 90 Day High Low • Feb 01New 90-day high: ৳84.30The company is up 5.0% from its price of ৳80.00 on 03 November 2020. The Bangladeshi market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 21% over the same period.
Is New 90 Day High Low • Nov 30New 90-day low: ৳66.50The company is down 17% from its price of ৳79.80 on 01 September 2020. The Bangladeshi market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.
Reported Earnings • Nov 26Third quarter 2020 earnings released: EPS ৳0.25The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ৳1.37b (up 18% from 3Q 2019). Net income: ৳58.7m (up 24% from 3Q 2019). Profit margin: 4.3% (up from 4.1% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Jul 07Beacon Pharmaceuticals Ltd. to Report Q3, 2020 Results on Jun 25, 2020Beacon Pharmaceuticals Ltd. announced that they will report Q3, 2020 results on Jun 25, 2020